Risk Assessment Tool in Predicting the Therapeutic Outcomes of Antiseizure Medication in Adults with Epilepsy
Rose Aniza Rusli,Mohd Makmor Bakry,Noraida Mohamed Shah,Xin Ling Loo,Stefanie Kar Yan Hung
DOI: https://doi.org/10.2147/tcrm.s467975
2024-08-27
Therapeutics and Clinical Risk Management
Abstract:Rose Aniza Rusli, 1, 2 Mohd Makmor Bakry, 1 Noraida Mohamed Shah, 1 Xin Ling Loo, 3 Stefanie Kar Yan Hung 4 1 Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2 Pharmacy Department, Hospital Shah Alam, Shah Alam, Selangor, Malaysia; 3 Pharmacy Department, Hospital Tengku Ampuan Rahimah, Klang, Selangor, Malaysia; 4 Neuromedical Unit, Hospital Tengku Ampuan Rahimah, Klang, Selangor, Malaysia Correspondence: Mohd Makmor Bakry, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, 50300, Malaysia, Tel +603 9289 7199, Fax +603 2698 3271, Email Aim: Identifying a patient's risk for poor outcomes after starting antiseizure medication (ASM) therapy is crucial in managing epilepsy pharmacologically. To date, there is a lack of designated tools to assess such risks. Purpose: To develop and validate a risk assessment tool for the therapeutic outcomes of ASM therapy. Patients and Methods: A cross-sectional study was carried out in a hospital-based specialist clinic from September 2022 to August 2023. Data was analyzed from patients' medical records and face-to-face assessments. The seizure control domain was determined from the patients' medical records while seizure severity (SS) and adverse effects (AE) of ASM were assessed using the Seizure Severity Questionnaire and the Liverpool Adverse Event Profile respectively. The developed tool was devised from prediction models using logistic and linear regressions. Concurrent validity and interrater reliability methods were employed for validity assessments. Results: A total of 397 patients were included in the analysis. For seizure control, the identified predictors include ≥ 10 years' epilepsy duration (OR:1.87,95% CI:1.10– 3.17), generalized onset (OR:7.42,95% CI:2.95– 18.66), focal onset seizure (OR:8.24,95% CI:2.98– 22.77), non-adherence (OR:3.55,95% CI:1.52– 8.27) and having ≥ 3 ASM (OR:3.29,95% CI:1.32– 8.24). Younger age at epilepsy onset (≤ 40) (OR:3.29,95% CI:1.32– 8.24) and neurological deficit (OR:3.55,95% CI:1.52– 8.27) were significant predictors for SS. For AE, the positive predictors were age > 35 (OR:0.12,95% CI:0.03– 0.20), < 13 years epilepsy duration (OR:2.89,95% CI:0.50– 5.29) and changes in ASM regimen (OR:2.93,95% CI: 0.24– 5.62). The seizure control domain showed a good discriminatory ability with a c-index of 0.711. From the Bonferroni (ANOVA) analysis, only SS predicted scores generated a linear plot against the mean of the actual scores. The AE domain was omitted from the final tool because it did not meet the requirements for validity assessment. Conclusion: This newly developed tool (RAS-TO) is a promising tool that could help healthcare providers in determining optimal treatment strategies for adults with epilepsy. Keywords: antiseizure medication, seizure control, risk assessment, therapeutic outcomes Achieving the desired therapeutic outcomes with antiseizure medication (ASM) therapy is of paramount importance in the management of epilepsy. The integral component of the outcomes is mainly related to the effectiveness and safety of the therapy. Researchers worldwide have been putting vast efforts into finding solutions to overcome poor or adverse therapeutic outcomes, which aligns with the International League Against Epilepsy (ILAE) aspirations. In practice, healthcare providers need to make decisions regarding optimizing the pharmacotherapy, which includes initiating and/or deferring the medication therapy, switching and altering the drug regimen and decisions on employing surgical interventions. 1 In order to aid the healthcare providers in executing the above workup, a clinical prediction tool, also known as a prognostic model, clinical prediction rule or risk score, is often used to estimate the probability of the patient experiencing a particular outcome, requiring further interventions as mentioned above. For epilepsy management, ILAE has outlined the definition of the outcome of therapeutic intervention, which includes the component of seizure freedom, treatment failure and undetermined outcome. An undetermined outcome is defined as an inadequate trial of the drug therapy or a lack of information in assessing the outcome. 2 To date, there is only one study that developed a tool to estimate the prognostic outcome of epilepsy (Scale to Estimate Prognostic Outcomes of Epilepsy — SEPE) with ASM therapy in an outpatient setting. This study used regression analysis of data retrospectively collected from a specialized epilepsy center and subsequent telephonic follow-up of the patient's seizure occurrence. The tool was able to predict -Abstract Truncated-
health care sciences & services